{"filing":{"accession_number":"0001193125-26-429465","cik":"0001796280","ticker":"ORIC","company_name":"Oric Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-10-23","report_date":"2026-10-23","primary_document":"d152009d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1796280/000119312526429465/d152009d8k.htm"},"events":[{"id":37438,"run_id":34510,"accession_number":"0001193125-26-429465","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"ORIC Pharmaceuticals disclosed positive Phase 1b clinical trial data for enozertinib (ORIC-114) in EGFR atypical NSCLC patients, showing 84% systemic ORR and 70% CNS ORR with favorable safety profile, and announced plans to initiate a global Phase 3 registrational trial (Redwood-1) in the first half of 2027.","company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","filing_date":"2026-10-23","form":"8-K","submitted_at":null,"items":[{"id":42150,"accession_number":"0001193125-26-429465","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"ORIC disclosed a clinical program update for enozertinib (ORIC-114) presented at ESMO Congress 2026, including Phase 1b trial data showing 84% systemic ORR and 70% CNS ORR in EGFR atypical NSCLC patients, with plans to initiate Phase 3 (Redwood-1) in 1H 2027. This is a material operational/clinical milestone for a clinical-stage biopharmaceutical company, representing significant progress in a lead program addressing a \u003e$2.5bn market opportunity, though it does not fit neatly into specific categories like earnings, M\u0026A, or governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T12:02:10.733880+00:00","company_name":"","ticker":null,"filing_date":""},{"id":42151,"accession_number":"0001193125-26-429465","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This Item 8.01 disclosure centers on clinical trial data and development milestones for enozertinib, a Phase 1b candidate in NSCLC. The company reports positive efficacy and safety data (84% systemic ORR, 70% CNS ORR, 88% 6-month PFS, no Grade 4/5 adverse events) and announces plans to initiate a global Phase 3 registrational trial (Redwood-1) in 1H 2027. While this is a material operational/clinical development event affecting investor assessment of the company's pipeline progress and commercial prospects, it does not fit the specific categories of earnings release, M\u0026A, restatement, auditor change, going concern, impairment, shareholder vote, delisting, bankruptcy, covenant breach, cybersecurity incident, dilutive issuance, litigation, debt issuance, dividend, or workforce reduction. The event is clearly operational (clinical development milestone) rather than financial, governance, legal, or existential in nature.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T12:02:10.733880+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":42150,"accession_number":"0001193125-26-429465","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"ORIC disclosed a clinical program update for enozertinib (ORIC-114) presented at ESMO Congress 2026, including Phase 1b trial data showing 84% systemic ORR and 70% CNS ORR in EGFR atypical NSCLC patients, with plans to initiate Phase 3 (Redwood-1) in 1H 2027. This is a material operational/clinical milestone for a clinical-stage biopharmaceutical company, representing significant progress in a lead program addressing a \u003e$2.5bn market opportunity, though it does not fit neatly into specific categories like earnings, M\u0026A, or governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T12:02:10.733880+00:00","company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","filing_date":"2026-10-23"},{"id":42151,"accession_number":"0001193125-26-429465","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This Item 8.01 disclosure centers on clinical trial data and development milestones for enozertinib, a Phase 1b candidate in NSCLC. The company reports positive efficacy and safety data (84% systemic ORR, 70% CNS ORR, 88% 6-month PFS, no Grade 4/5 adverse events) and announces plans to initiate a global Phase 3 registrational trial (Redwood-1) in 1H 2027. While this is a material operational/clinical development event affecting investor assessment of the company's pipeline progress and commercial prospects, it does not fit the specific categories of earnings release, M\u0026A, restatement, auditor change, going concern, impairment, shareholder vote, delisting, bankruptcy, covenant breach, cybersecurity incident, dilutive issuance, litigation, debt issuance, dividend, or workforce reduction. The event is clearly operational (clinical development milestone) rather than financial, governance, legal, or existential in nature.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T12:02:10.733880+00:00","company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","filing_date":"2026-10-23"}]}